Raga Deepak Reddy Palagiri, MD
Pulmonary Disease · Conway, ARNPI 1831542737
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,976 of the $3,754 with a category attached, or 79.3%. It is spread thinly across 21 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for pulmonary disease clinicians in AR, where the typical reported total is $3,332.
Across 162 payments — averaging $23.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Noah Medical Corporation$755
- GSK$746
- AstraZeneca$513
- Boehringer Ingelheim$269
- Sanofi$237
- Electromed, Inc.$197
- plus $1K from 15 others
What the payments were for
- Travel & lodging$75520%
- Food & beverage$2,97679%
- Education$231%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Noah Medical Corporation | 1 | $755 |
| GSK | 49 | $746 |
| AstraZeneca | 28 | $513 |
| Boehringer Ingelheim | 11 | $269 |
| Sanofi | 12 | $237 |
| Electromed, Inc. | 7 | $197 |
| Regeneron Healthcare Solutions, Inc. | 8 | $165 |
| Actelion Pharmaceuticals US, Inc. | 7 | $157 |
| Mylan Specialty L.p. | 7 | $120 |
| Philips North America LLC | 5 | $97 |
| United Therapeutics Corporation | 5 | $97 |
| Grifols USA, LLC | 5 | $93 |
| Bayer | 3 | $58 |
| Mallinckrodt Hospital Products Inc. | 3 | $57 |
| Baxter Healthcare | 3 | $54 |
| Verona Pharma, Inc. | 2 | $35 |
| Insmed, Inc. | 2 | $34 |
| Genentech USA, Inc. | 1 | $20 |
| Pfizer | 1 | $20 |
| Viatris Specialty LLC | 1 | $19 |
| Abiomed | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,754 in reported general payments places this provider in the 50th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 342 | $248,539 |
| OfevNintedanib Esylate | 11 | $132,183 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 93 | $60,338 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 118 | $59,347 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 91 | $44,842 |
| Dupixent PenDupilumab | 11 | $43,090 |
| SymbicortBudesonide/Formoterol Fumarate | 72 | $25,190 |
| Varenicline Tartrate | 29 | $13,406 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 69 | $13,306 |
| Spiriva RespimatTiotropium Bromide | 19 | $10,578 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,482 |
| BreynaBudesonide/Formoterol Fumarate | 27 | $6,617 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 145 | $4,407 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 13 | $3,984 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 26 | $3,892 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $746 | $301,863452 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $269 | $202,107148 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $513 | $85,528165 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Conway
- Ladly AbrahamConway$371K
- Tyrone LeeConway$4K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
- Mark SiffordJonesboro$20K
- Zafirah SalmanNorth Little Rock$18K
- Dominika SzwedoNorth Little Rock$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.